Tag: Amycretin

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Amycretin

Is Novo Nordisk the Best Healthcare Stock for You? | The Motley Fool

Added to Collection on: 2024-03-31 22:19:21

Tags for this article:

Novo Nordisk
Peptide hormones
PEPTIDE THERAPEUTICS
Semaglutide
Amycretin
Catalent
Nordisk
Anti-obesity medication
Pharmaceutical industry
Novo Holdings A/S
GLP-1 receptor agonist

Click the tags to see associated articles and topics

View Article Details
Weight-Loss Drug Startup Metsera Launches with $290M, Looks to Tap Lucrative Obesity Market

Added to Collection on: 2024-04-18 15:16:24

Tags for this article:

PEPTIDE THERAPEUTICS
Peptide hormones
GLP-1 receptor agonist
Glucagon-like peptide-1
Anti-obesity medication
VK2735
Novo Nordisk
GLP
Amycretin
GLP1 poly-agonist peptides

Click the tags to see associated articles and topics

View Article Details
Pfizer selects once-daily GLP-1 for its obesity push - Pharmaphorum

Added to Collection on: 2024-07-12 20:13:39

Tags for this article:

PEPTIDE THERAPEUTICS
Peptide hormones
Semaglutide
GLP-1 receptor agonist
Amycretin
Anti-obesity medication
Tirzepatide
Glucagon-like peptide-1
Novo Nordisk
Orforglipron
Danuglipron
Ro
Eli Lilly
Pfizer
GLP-1

Click the tags to see associated articles and topics

View Article Details
Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data

Added to Collection on: 2024-07-29 14:01:08

Tags for this article:

PEPTIDE THERAPEUTICS
Novo Nordisk
Anti-obesity medication
Semaglutide
Obesity
Weight loss
Eli Lilly and Company
Ro
Pharmaceutical industry
Amycretin
GLP-1 receptor agonist
Eli Lilly
Roche Pharmaceuticals

Click the tags to see associated articles and topics

View Article Details
Novo Nordisk to meet Drug Demand with $220M Expansion

Added to Collection on: 2024-08-22 18:12:14

Tags for this article:

Novo Nordisk
Semaglutide
Kalundborg
NNE
Nordisk
Novo Holdings A/S
Amycretin

Click the tags to see associated articles and topics

View Article Details
Verdiva Bio launches with $411m in funding to advance obesity drugs

Added to Collection on: 2025-01-09 15:44:13

Tags for this article:

Peptide hormones
Anti-diabetic drugs
Eli Lilly and Company
Research and development in the United States
Amylin
Dual amylin and calcitonin receptor agonists
Glucagon-like peptide-1
Medication
Amycretin
Anti-obesity medication
Atlantic

Click the tags to see associated articles and topics

View Article Details